Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Expensive Performer
1616.0000 14.50 (0.91%)
NSE Jun 15, 2026 15:31 PM
Volume: 217.5K
 

1616.00
0.91%
Emkay
DLPL reported a steady Q4, with EBITDA beating street/our estimates by 6% and adj PAT improving 34% on YoY basis. Strong performance in core markets (Delhi NCR), buoyed by network expansion, offset the persistent muted performance of Suburban (mid-single digit revenue growth).
Number of FII/FPI investors decreased from 378 to 351 in Mar 2026 qtr
More from Dr. Lal Pathlabs Ltd.
Recommended